Annual Report & ACCOUNTS for the year ended 30 June 2014

HYR 2014

A key strategic priority for the Group is the delivery and strength of the pipeline. The following chart outlines the timeline, status and progress of the major projects. Collectively the pipeline is expected to deliver in excess of £40 million annual sales assuming all products reach maturity.

First Expected
Launch(1)
Therapeutic CategorySpeciesTerritoryManufacturingPre-ClinicalClinicalFile
2014Lameness(2)HorseInternationalOutsourced
2015Anti-microbialsSeveralEUOutsourced
Endocrinology(3)DogsInternationalIn-house
Anti-microbialsPoultryEUIn-house
EndocrinologyDogsEUOutsourced
2016Anti-microbialsSeveralEUIn-house
Endocrinology(3)DogsInternationalIn-house
2017Anti-microbialsCattleEUIn-house
DermatologyDogsInternationalIn-house
Anti-microbialsPoultryEUIn-house
2018+OphthalmologyDogsInternationalOutsourced
Anti-microbialsPoultryEUIn-house
CardiovascularDogsEUIn-house
EndocrinologyCatsInternationalOutsourced
EndocrinologyDogsInternationalIn-house
DermatologyDogsUSIn-house

Key:

Previous Year

Current Year

New

(1) Calendar year (2) Osphos (3) Identical product with first launch in EU and subsequent launch in US

The first expected launch date is a management estimate that may not be met due to regulatory, manufacturing or other issues.